The role of Impella percutaneous left ventricular assist device in the management of cardiogenic shock: A matter of where and when

Citations Over Time

Abstract

Key Points Temporary mechanical circulatory support with Impella pLVAD has increasingly been used in the management of cardiogenic shock in recent years, despite conflicting evidence supporting improved clinical outcomes. This study shows that the use of pLVAD was associated with both an improvement in hemodynamics as well as a decrease in vasopressor and inotropic support, but the need for escalation of MCS to VA‐ECMO was not uncommon and independently associated with a need for higher vasopressor‐inotropic support on admission. Earlier pLVAD implantation was associated with a trend toward reduction in mortality, but further randomized trials are needed to assess the appropriate use and efficacy of the Impella device in treating patients with CS.

Related Papers

• → Complications associated with mechanical circulatory support(2020)56 cited
• → Favorable Effects of Impella on Takotsubo Syndrome Complicated with Cardiogenic Shock(2021)21 cited
• → Impella RP for treatment of right ventricular shock: Appropriate unloading never gets old(2020)4 cited
• → The Impella(R) LP 5.0 as a bridge to long-term circulatory support(2009)33 cited
• First-in-Man Percutaneous Transaxillary Artery Placement and Removal of the Impella 5.0 Mechanical Circulatory Support Device.(2017)